医学
微生物群
肠道微生物群
炎症性肠病
粪便细菌疗法
心理干预
重症监护医学
疾病
免疫系统
生物信息学
肠道菌群
免疫学
内科学
艰难梭菌
抗生素
微生物学
生物
精神科
作者
Ashwin N. Ananthakrishnan,Kevin Whelan,Jessica R. Allegretti,Harry Sokol
标识
DOI:10.1016/j.cgh.2024.05.049
摘要
Inflammatory bowel disease (IBD) comprises chronic and relapsing disorders of the gastrointestinal tract, characterized by dysregulated immune responses to the gut microbiome. The gut microbiome and diet are key environmental factors that influence the onset and progression of IBD and can be leveraged for treatment. In this review, we summarize the current evidence on the role of the gut microbiome and diet in IBD pathogenesis, and the potential of microbiome-directed therapies and dietary interventions to improve IBD outcomes. We discuss available data and the advantages and drawbacks of the different approaches to manipulate the gut microbiome, such as fecal microbiota transplantation, next-generation and conventional probiotics, and postbiotics. We also review the use of diet as a therapeutic tool in IBD, including the effects in induction and maintenance, special diets, and exclusive enteral nutrition. Finally, we highlight the challenges and opportunities for the translation of diet and microbiome interventions into clinical practice, such as the need for personalization, manufacturing and regulatory hurdles, and the specificity to take into account for clinical trial design.
科研通智能强力驱动
Strongly Powered by AbleSci AI